SRPT vs. DAVE
SRPT (Sarepta Therapeutics, Inc.) and DAVE (Dave Inc.) are both stocks. SRPT operates in Biotechnology (Healthcare), while DAVE operates in Credit Services (Financial Services). Over the past 5 years, SRPT returned -26.18%/yr vs 3.39%/yr for DAVE. Their 0.19 correlation means their historical movements had little consistent relationship.
Performance
SRPT vs. DAVE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SRPT achieves a -30.95% return, which is significantly lower than DAVE's 68.33% return.
SRPT
- 1D
- -4.50%
- 1M
- -22.93%
- 6M
- -26.94%
- YTD
- -30.95%
- 1Y
- -6.60%
- 3Y*
- -48.30%
- 5Y*
- -26.18%
- 10Y*
- -5.26%
- ALL TIME*
- -3.56%
DAVE
- 1D
- -1.31%
- 1M
- -3.79%
- 6M
- 127.68%
- YTD
- 68.33%
- 1Y
- 60.14%
- 3Y*
- 285.61%
- 5Y*
- 3.39%
- 10Y*
- —
- ALL TIME*
- 3.33%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
DAVE Dave Inc. | $172.88M | $187.81M | $183.81M |
| $46.66M | $54.69M | $59.65M |
SRPT vs. DAVE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
SRPT Sarepta Therapeutics, Inc. | -30.95% | -82.30% | 26.09% | -25.58% | 43.90% | 26.94% |
DAVE Dave Inc. | 68.33% | 154.73% | 936.61% | -9.64% | -97.17% | 4.59% |
Correlation
The correlation between SRPT and DAVE is 0.23, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.23 |
Correlation (3Y) Balances recent behavior with more history. | 0.23 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.19 |
Correlation (All Time) Calculated using the full available price history since Apr 26, 2021 | 0.19 |
Fundamentals
SRPT:
$1.57B
DAVE:
$5.01B
SRPT:
$0.60
DAVE:
$15.57
SRPT:
24.89
DAVE:
23.94
SRPT:
0.74
DAVE:
9.77
SRPT:
1.20
DAVE:
26.34
SRPT:
$2.18B
DAVE:
$551.52M
SRPT:
$751.34M
DAVE:
$427.68M
SRPT:
$107.91M
DAVE:
$165.95M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SRPT vs. DAVE — Risk / Return Rank
SRPT
DAVE
SRPT vs. DAVE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Dave Inc. (DAVE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SRPT | DAVE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.96 | ||
| Sortino ratioReturn per unit of downside risk | -1.08 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.19 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | -0.24 | 1.49 | -1.74 |
| Martin ratioReturn relative to average drawdown | -0.45 | 3.26 | -3.70 |
Loading charts...
Drawdowns
SRPT vs. DAVE - Drawdown Comparison
The maximum SRPT drawdown since its inception was -98.17%, roughly equal to the maximum DAVE drawdown of -99.01%. Use the drawdown chart below to compare losses from any high point for SRPT and DAVE.
Loading charts...
Drawdown Indicators
| SRPT | DAVE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.17% | -99.01% | +0.84% |
Max Drawdown (1Y)Largest decline over 1 year | -39.22% | -39.11% | -0.11% |
Max Drawdown (3Y)Largest decline over 3 years | -92.72% | -44.67% | -48.05% |
Max Drawdown (5Y)Largest decline over 5 years | -92.72% | -99.01% | +6.29% |
Max Drawdown (10Y)Largest decline over 10 years | -93.33% | — | — |
Current DrawdownCurrent decline from peak | -91.69% | -18.56% | -73.13% |
Average DrawdownAverage peak-to-trough decline | -68.27% | -67.63% | -0.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.23% | 17.88% | +3.35% |
Volatility
SRPT vs. DAVE - Volatility Comparison
Sarepta Therapeutics, Inc. (SRPT) and Dave Inc. (DAVE) have volatilities of 13.90% and 14.54%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SRPT | DAVE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.90% | 14.54% | -0.64% |
Volatility (6M)Calculated over the trailing 6-month period | 51.20% | 48.39% | +2.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 80.79% | 69.38% | +11.41% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 70.03% | 99.00% | -28.97% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 70.26% | 96.44% | -26.18% |
Dividends
SRPT vs. DAVE - Dividend Comparison
Neither SRPT nor DAVE has paid dividends to shareholders.
Financials
SRPT vs. DAVE - Financials Comparison
This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Dave Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SRPT vs. DAVE - Profitability Comparison
SRPT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Sarepta Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 730.80M. Therefore, the gross margin over that period was 0.0%.
DAVE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Dave Inc. reported a gross profit of 120.00M and revenue of 147.59M. Therefore, the gross margin over that period was 81.3%.
SRPT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Sarepta Therapeutics, Inc. reported an operating income of 358.43M and revenue of 730.80M, resulting in an operating margin of 49.1%.
DAVE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Dave Inc. reported an operating income of 21.15M and revenue of 147.59M, resulting in an operating margin of 14.3%.
SRPT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Sarepta Therapeutics, Inc. reported a net income of 330.96M and revenue of 730.80M, resulting in a net margin of 45.3%.
DAVE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Dave Inc. reported a net income of 57.94M and revenue of 147.59M, resulting in a net margin of 39.3%.
Frequently Asked Questions
SRPT and DAVE have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DAVE has higher volatility (14.54%) compared to SRPT (13.90%). In terms of maximum drawdown, SRPT dropped -98.17% vs DAVE's -99.01%.
DAVE currently has the higher Sharpe Ratio (0.84 vs -0.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SRPT and DAVE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer